CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

Loading news article.

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027 | WAPE

CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027

Article summary

Related companies

Comments —